Dr Caleb Alexander examines the US Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's Disease.

When assessing new techniques for use with marginalized populations, it is critical to consider costs and benefits free of unexamined biases. Anything less is discriminatory and unjust.